Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1821–1827. doi: 10.1038/bjc.1996.637

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.

A Weaver 1, E Wrigley 1, A Watson 1, J Chang 1, C D Collins 1, B Jenkins 1, C Gill 1, R Pettengell 1, T M Dexter 1, N G Testa 1, D Crowther 1
PMCID: PMC2077231  PMID: 8956800

Abstract

We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone (10 micrograms kg-1), the apheresis harvest contained a median CFU-GM count of 45 x 10(4) kg-1 and 2 x 10(6) kg-1 CD34+ cells. Treatment with filgrastim (5 micrograms kg-1) following cyclophosphamide (3 g m-2) resulted in a harvest containing 66 x 10(4) kg-1 CFU-GM and 2.4 x 10(6) kg-1 CD34+ cells. There was no statistically significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide (900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval between treatment cycles to 2 weeks. However, at this dose intensity less than a third of patients received their planned treatment on time. All the delays were due to thrombocytopenia.

Full text

PDF
1821

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews R. G., Bartelmez S. H., Knitter G. H., Myerson D., Bernstein I. D., Appelbaum F. R., Zsebo K. M. A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. Blood. 1992 Aug 15;80(4):920–927. [PubMed] [Google Scholar]
  2. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  3. Dührsen U., Villeval J. L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988 Dec;72(6):2074–2081. [PubMed] [Google Scholar]
  4. Feremans W., Le Moine F., Ravoet C., Lambermont M., Bastin G., Delville J. P., Pradier O., Dupont E., Capel P. Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am J Hematol. 1994 Oct;47(2):135–138. doi: 10.1002/ajh.2830470214. [DOI] [PubMed] [Google Scholar]
  5. Gianni A. M., Siena S., Bregni M., Tarella C., Stern A. C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989 Sep 9;2(8663):580–585. doi: 10.1016/s0140-6736(89)90711-3. [DOI] [PubMed] [Google Scholar]
  6. Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121–141. [PubMed] [Google Scholar]
  7. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  8. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  9. Murphy D., Crowther D., Renninson J., Prendiville J., Ranson M., Lind M., Patel U., Dougal M., Buckley C. H., Tindall V. R. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol. 1993 May;4(5):377–383. doi: 10.1093/oxfordjournals.annonc.a058516. [DOI] [PubMed] [Google Scholar]
  10. Ngan H. Y., Choo Y. C., Cheung M., Wong L. C., Ma H. K., Collins R., Fung C., Ng C. S., Wong V., Ho H. C. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy. 1989;35(3):221–227. doi: 10.1159/000238673. [DOI] [PubMed] [Google Scholar]
  11. Parkin D. M., Lärä E., Muir C. S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988 Feb 15;41(2):184–197. doi: 10.1002/ijc.2910410205. [DOI] [PubMed] [Google Scholar]
  12. Russell N. H., Hunter A., Rogers S., Hanley J., Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet. 1993 Jun 5;341(8858):1482–1482. doi: 10.1016/0140-6736(93)90929-b. [DOI] [PubMed] [Google Scholar]
  13. Siena S., Bregni M., Brando B., Belli N., Ravagnani F., Gandola L., Stern A. C., Lansdorp P. M., Bonadonna G., Gianni A. M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood. 1991 Jan 15;77(2):400–409. [PubMed] [Google Scholar]
  14. Socinski M. A., Cannistra S. A., Elias A., Antman K. H., Schnipper L., Griffin J. D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28;1(8596):1194–1198. doi: 10.1016/s0140-6736(88)92012-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES